US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SPYRE THERAPEUTICS INC

24.36

+0.10000.41%

Volume:26.59K

Turnover:643.45K

Market Cap:1.89B

PE:-8.54

High:24.57

Open:24.10

Low:23.65

Close:24.26

52wk High:40.26

52wk Low:10.91

Shares:77.50M

Float Shares:63.83M

Volume Ratio:0.37

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.8512

EPS(LYR):-3.1802

ROE:-49.83%

ROA:-28.48%

PB:6.29

PE(LYR):-7.66

Loading ...

Overview Company News Filings

Spyre Therapeutics Announces Promising Phase 1 Results for Novel Anti-TL1A Antibody SPY002 in Inflammatory Bowel Disease at UEGW 2025

Press Release: Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics initiated with a Buy at Deutsche Bank

Spyre Therapeutics Inc : Deutsche Bank Initiates Coverage With Buy Rating; Target Price $43

THOMSON REUTERS

JonesTrading Remains a Hold on Spyre Therapeutics (SYRE)

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE), Xtant Medical Holdings (XTNT) and Akeso, Inc. (HK:9926)

Spyre Therapeutics Launches Phase 2 SKYWAY Trial of Pioneering Anti-TL1A Antibody SPY072 for Rheumatic Diseases

Spyre Therapeutics Doses First Patient in Pioneering Phase 2 Skyway Basket Trial of Spy072, the First Anti-Tl1a Antibody Studied in Rheumatic Diseases

THOMSON REUTERS

CFO Scott L. Burrows Reports Disposal of Common Shares of Spyre Therapeutics Inc

Stock Track | Spyre Therapeutics (SYRE) Plummets 5.16% as Q2 Results Show One-Time Gain and Rising R&D Costs

IBM rolls out new chips and servers, aims for simplified AI

U.S. RESEARCH ROUNDUP-American Airlines, Jabil, Lennar

Spyre Therapeutics Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases

Spyre Therapeutics Inc. to Announce Results for the First Quarter 2025

Spyre Therapeutics Announces Inducement Stock Option Grants for New Employees Under 2018 Equity Plan

Spyre Therapeutics Inc. Convened Annual Stockholders Meeting

Spyre Therapeutics Inc. to Participate in Jefferies Global Healthcare Conference

Spyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SYRE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","market":"US","secType":"STK","nameCN":"SPYRE THERAPEUTICS INC","latestPrice":24.36,"timestamp":1761919371307,"preClose":24.26,"halted":0,"volume":26594,"delay":0,"floatShares":63829799,"shares":77495600,"eps":-2.851176,"marketStatus":"Trading","change":0.1,"latestTime":"10-31 10:02:53 EDT","open":24.1,"high":24.57,"low":23.65,"amount":643445.872288,"amplitude":0.037923,"askPrice":24.58,"askSize":518,"bidPrice":24.17,"bidSize":34,"shortable":3,"etf":0,"ttmEps":-2.851176,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1761940800000},"marketStatusCode":2,"adr":0,"listingDate":1460001600000,"exchange":"NASDAQ","adjPreClose":24.26,"preHourTrading":{"tag":"盘前","latestPrice":24.31,"preClose":24.26,"latestTime":"09:11 EDT","volume":613,"amount":14852.099924,"timestamp":1761916299011},"postHourTrading":{"tag":"盘后","latestPrice":24.26,"preClose":24.26,"latestTime":"16:29 EDT","volume":10493,"amount":254559.24,"timestamp":1761856197647},"volumeRatio":0.366459,"impliedVol":0.4427,"impliedVolPercentile":0.236},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","floatShares":63829799,"roa":"-28.48%","roe":"-49.83%","lyrEps":-3.180151,"volumeRatio":0.366459,"shares":77495600,"dividePrice":0,"high":24.57,"amplitude":0.037923,"preClose":24.26,"low":23.65,"week52Low":10.91,"pbRate":"6.29","week52High":40.26,"institutionHeld":0,"latestPrice":24.36,"committee":-0.876812,"eps":-2.851176,"divideRate":0,"volume":26594,"delay":0,"ttmEps":-2.851176,"open":24.1,"prevYearClose":23.28,"prevWeekClose":23.37,"prevMonthClose":16.76,"prevQuarterClose":16.76,"fiveDayClose":23.37,"twentyDayClose":15.89,"sixtyDayClose":15.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-05","symbol":"SYRE","fiscalQuarterEnding":"2025/06","expectedEps":-0.73,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-05-08","symbol":"SYRE","fiscalQuarterEnding":"2025/03","expectedEps":-0.76,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.74},{"market":"US","date":"2025-02-27","symbol":"SYRE","fiscalQuarterEnding":"2024/12","expectedEps":-1.1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":-0.81},{"market":"US","date":"2024-11-07","symbol":"SYRE","fiscalQuarterEnding":"2024/09","expectedEps":-0.8,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.36},{"market":"US","date":"2024-08-07","symbol":"SYRE","fiscalQuarterEnding":"2024/06","expectedEps":-0.9,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":-0.86}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6154,"buy":0.3077,"hold":0.0769,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6154,"analysts":13,"updateTime":1758859200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SYRE","date":"2025-10-30","current":-8.50877,"percent":0.037578,"low":-10.261647,"twenty":-6.677726,"median":-4.695701,"eighty":-3.698293,"high":-0.199399,"avg":-5.091711,"sd":1.805231,"marketCap":1846719051},"quantilePoints":[{"date":"2023-12-01","current":-1.902619,"twenty":-1.228042,"median":-0.216176,"eighty":-0.20611,"marketCap":560191990},{"date":"2023-12-08","current":-2.024974,"twenty":-2.048834,"median":-1.98164,"eighty":-0.890753,"marketCap":596217199},{"date":"2023-12-15","current":-1.815535,"twenty":-2.023412,"median":-1.966856,"eighty":-1.735642,"marketCap":534551743},{"date":"2023-12-22","current":-2.106706,"twenty":-2.023412,"median":-1.950531,"eighty":-1.82549,"marketCap":620281740},{"date":"2023-12-29","current":-2.507984,"twenty":-2.09023,"median":-1.996425,"eighty":-1.840422,"marketCap":738430643},{"date":"2024-01-05","current":-2.757559,"twenty":-2.278228,"median":-2.002935,"eighty":-1.873937,"marketCap":811913497},{"date":"2024-01-12","current":-2.567931,"twenty":-2.588728,"median":-2.024974,"eighty":-1.89995,"marketCap":756080936},{"date":"2024-01-19","current":-2.66458,"twenty":-2.653814,"median":-2.09023,"eighty":-1.902486,"marketCap":784537532},{"date":"2024-01-26","current":-3.303198,"twenty":-2.742878,"median":-2.292052,"eighty":-1.915254,"marketCap":972567189},{"date":"2024-02-02","current":-3.16373,"twenty":-3.116751,"median":-2.567931,"eighty":-1.947266,"marketCap":931503241},{"date":"2024-02-09","current":-2.89825,"twenty":-3.138772,"median":-2.61809,"eighty":-1.978684,"marketCap":853337655},{"date":"2024-02-16","current":-2.760005,"twenty":-3.112591,"median":-2.66458,"eighty":-1.997649,"marketCap":812633917},{"date":"2024-02-23","current":-2.496973,"twenty":-3.08641,"median":-2.66458,"eighty":-2.000865,"marketCap":735188752},{"date":"2024-03-01","current":-3.357028,"twenty":-3.117974,"median":-2.696389,"eighty":-2.009323,"marketCap":988416432},{"date":"2024-03-08","current":-4.14553,"twenty":-3.186241,"median":-2.748383,"eighty":-2.021849,"marketCap":1404464057},{"date":"2024-03-15","current":-4.473117,"twenty":-3.315921,"median":-2.757559,"eighty":-2.032927,"marketCap":1515447446},{"date":"2024-03-22","current":-4.253303,"twenty":-3.374155,"median":-2.84075,"eighty":-2.069838,"marketCap":1440976508},{"date":"2024-03-28","current":-3.948124,"twenty":-3.948124,"median":-2.884793,"eighty":-2.09023,"marketCap":1337584817},{"date":"2024-04-05","current":-3.822655,"twenty":-3.997689,"median":-2.933117,"eighty":-2.106706,"marketCap":1295077328},{"date":"2024-04-12","current":-4.169482,"twenty":-4.017483,"median":-2.950857,"eighty":-2.22293,"marketCap":1412578691},{"date":"2024-04-19","current":-3.844264,"twenty":-4.019298,"median":-3.071974,"eighty":-2.361175,"marketCap":1302398285},{"date":"2024-04-26","current":-3.508242,"twenty":-4.017483,"median":-3.149049,"eighty":-2.496973,"marketCap":1188557401},{"date":"2024-05-03","current":-4.312212,"twenty":-4.026871,"median":-3.180093,"eighty":-2.505537,"marketCap":1460934345},{"date":"2024-05-10","current":-4.183809,"twenty":-4.050631,"median":-3.290964,"eighty":-2.507984,"marketCap":1417432578},{"date":"2024-05-17","current":-4.180278,"twenty":-4.096445,"median":-3.334395,"eighty":-2.567931,"marketCap":1522561849},{"date":"2024-05-24","current":-3.614061,"twenty":-4.096445,"median":-3.364368,"eighty":-2.569154,"marketCap":1316331249},{"date":"2024-05-31","current":-4.872934,"twenty":-4.111605,"median":-3.38639,"eighty":-2.608303,"marketCap":1774844320},{"date":"2024-06-07","current":-4.694469,"twenty":-4.171641,"median":-3.527045,"eighty":-2.61809,"marketCap":1709842869},{"date":"2024-06-14","current":-4.393309,"twenty":-4.193693,"median":-3.59738,"eighty":-2.63375,"marketCap":1600152919},{"date":"2024-06-21","current":-3.360163,"twenty":-4.181695,"median":-3.573485,"eighty":-2.653814,"marketCap":1223855454},{"date":"2024-06-28","current":-3.277902,"twenty":-4.180281,"median":-3.545724,"eighty":-2.666048,"marketCap":1193893847},{"date":"2024-07-05","current":-3.553965,"twenty":-4.180278,"median":-3.545724,"eighty":-2.674367,"marketCap":1294442968},{"date":"2024-07-12","current":-4.13816,"twenty":-4.17596,"median":-3.564426,"eighty":-2.694186,"marketCap":1507221157},{"date":"2024-07-19","current":-4.113063,"twenty":-4.180278,"median":-3.593701,"eighty":-2.712782,"marketCap":1498080328},{"date":"2024-07-26","current":-4.387732,"twenty":-4.219183,"median":-3.614061,"eighty":-2.731867,"marketCap":1598121624},{"date":"2024-08-02","current":-3.651563,"twenty":-4.192391,"median":-3.674487,"eighty":-2.752053,"marketCap":1329990636},{"date":"2024-08-09","current":-6.773008,"twenty":-4.238871,"median":-3.689208,"eighty":-2.757559,"marketCap":1259650875},{"date":"2024-08-16","current":-7.111659,"twenty":-4.267009,"median":-3.707046,"eighty":-2.757559,"marketCap":1322633418},{"date":"2024-08-23","current":-6.972375,"twenty":-4.305721,"median":-3.744862,"eighty":-2.758537,"marketCap":1296729308},{"date":"2024-08-30","current":-7.851774,"twenty":-4.372067,"median":-3.796365,"eighty":-2.792303,"marketCap":1460280752},{"date":"2024-09-06","current":-7.655166,"twenty":-4.395693,"median":-3.839237,"eighty":-2.844176,"marketCap":1423715511},{"date":"2024-09-13","current":-8.038472,"twenty":-4.515004,"median":-3.909092,"eighty":-2.863261,"marketCap":1495003126},{"date":"2024-09-20","current":-8.260242,"twenty":-4.753435,"median":-3.923931,"eighty":-2.887484,"marketCap":1536248103},{"date":"2024-09-27","current":-7.800275,"twenty":-4.893011,"median":-3.931452,"eighty":-2.904612,"marketCap":1450702965},{"date":"2024-10-04","current":-7.980976,"twenty":-5.268067,"median":-3.990592,"eighty":-2.931282,"marketCap":1484309983},{"date":"2024-10-11","current":-7.857771,"twenty":-6.760445,"median":-4.004311,"eighty":-2.936176,"marketCap":1461396107},{"date":"2024-10-18","current":-8.969358,"twenty":-6.959266,"median":-4.01434,"eighty":-2.939112,"marketCap":1668130191},{"date":"2024-10-25","current":-9.530627,"twenty":-7.262959,"median":-4.019298,"eighty":-2.969942,"marketCap":1772515627},{"date":"2024-11-01","current":-9.303382,"twenty":-7.505129,"median":-4.04736,"eighty":-3.046528,"marketCap":1730252255},{"date":"2024-11-08","current":-9.47125,"twenty":-7.585076,"median":-4.070861,"eighty":-3.057293,"marketCap":2035390531},{"date":"2024-11-15","current":-6.988263,"twenty":-7.603794,"median":-4.087936,"eighty":-3.101825,"marketCap":1501791624},{"date":"2024-11-22","current":-7.566995,"twenty":-7.593388,"median":-4.106049,"eighty":-3.128495,"marketCap":1626162294},{"date":"2024-11-29","current":-7.766414,"twenty":-7.602508,"median":-4.133831,"eighty":-3.149049,"marketCap":1669017834},{"date":"2024-12-06","current":-7.397625,"twenty":-7.602508,"median":-4.146835,"eighty":-3.16373,"marketCap":1589764437},{"date":"2024-12-13","current":-6.589022,"twenty":-7.597044,"median":-4.169482,"eighty":-3.166361,"marketCap":1415994026},{"date":"2024-12-20","current":-6.517996,"twenty":-7.595055,"median":-4.180278,"eighty":-3.169847,"marketCap":1400730409},{"date":"2024-12-27","current":-6.466093,"twenty":-7.588386,"median":-4.182047,"eighty":-3.186241,"marketCap":1389576227},{"date":"2025-01-03","current":-6.651853,"twenty":-7.58308,"median":-4.215671,"eighty":-3.191991,"marketCap":1429496457},{"date":"2025-01-10","current":-6.135549,"twenty":-7.579794,"median":-4.247699,"eighty":-3.203592,"marketCap":1318541701},{"date":"2025-01-17","current":-5.632904,"twenty":-7.573901,"median":-4.253955,"eighty":-3.236074,"marketCap":1210522256},{"date":"2025-01-24","current":-5.900617,"twenty":-7.564263,"median":-4.27898,"eighty":-3.264517,"marketCap":1268054352},{"date":"2025-01-31","current":-6.280332,"twenty":-7.548513,"median":-4.304099,"eighty":-3.280514,"marketCap":1349655997},{"date":"2025-02-07","current":-6.187452,"twenty":-7.528128,"median":-4.345056,"eighty":-3.293411,"marketCap":1329695883},{"date":"2025-02-14","current":-6.26121,"twenty":-7.522652,"median":-4.382852,"eighty":-3.305947,"marketCap":1345546562},{"date":"2025-02-21","current":-5.815932,"twenty":-7.518271,"median":-4.394799,"eighty":-3.316941,"marketCap":1249855423},{"date":"2025-02-28","current":-5.708297,"twenty":-7.512359,"median":-4.473117,"eighty":-3.319102,"marketCap":1187428551},{"date":"2025-03-07","current":-5.647447,"twenty":-7.483663,"median":-4.605135,"eighty":-3.349687,"marketCap":1174770683},{"date":"2025-03-14","current":-5.227293,"twenty":-7.452562,"median":-4.749486,"eighty":-3.357028,"marketCap":1087371120},{"date":"2025-03-21","current":-5.264962,"twenty":-7.449529,"median":-4.833391,"eighty":-3.360163,"marketCap":1095206943},{"date":"2025-03-28","current":-5.198317,"twenty":-7.397625,"median":-4.89803,"eighty":-3.364368,"marketCap":1081343564},{"date":"2025-04-04","current":-3.706047,"twenty":-7.375771,"median":-4.833391,"eighty":-3.376602,"marketCap":770924425},{"date":"2025-04-11","current":-3.540883,"twenty":-7.371109,"median":-4.749486,"eighty":-3.378289,"marketCap":736567355},{"date":"2025-04-17","current":-3.671275,"twenty":-7.352984,"median":-4.694469,"eighty":-3.38477,"marketCap":763691357},{"date":"2025-04-25","current":-4.094327,"twenty":-7.328784,"median":-4.51381,"eighty":-3.412624,"marketCap":851693676},{"date":"2025-05-02","current":-4.378293,"twenty":-7.296115,"median":-4.473117,"eighty":-3.422161,"marketCap":910763726},{"date":"2025-05-09","current":-4.072986,"twenty":-7.269514,"median":-4.422481,"eighty":-3.450063,"marketCap":850985210},{"date":"2025-05-16","current":-4.384959,"twenty":-7.258044,"median":-4.393309,"eighty":-3.492778,"marketCap":916167055},{"date":"2025-05-23","current":-4.353184,"twenty":-7.252035,"median":-4.386346,"eighty":-3.506946,"marketCap":909528164},{"date":"2025-05-30","current":-4.491839,"twenty":-7.242247,"median":-4.381626,"eighty":-3.527827,"marketCap":938497873},{"date":"2025-06-06","current":-4.800924,"twenty":-7.228256,"median":-4.393309,"eighty":-3.543713,"marketCap":1003076183},{"date":"2025-06-13","current":-5.115786,"twenty":-7.156112,"median":-4.413455,"eighty":-3.545748,"marketCap":1068861565},{"date":"2025-06-20","current":-4.356073,"twenty":-7.062301,"median":-4.413455,"eighty":-3.549094,"marketCap":910131699},{"date":"2025-06-27","current":-4.627605,"twenty":-6.984824,"median":-4.413846,"eighty":-3.558149,"marketCap":966864047},{"date":"2025-07-03","current":-4.5525,"twenty":-6.978207,"median":-4.413846,"eighty":-3.566238,"marketCap":951172121},{"date":"2025-07-11","current":-4.610273,"twenty":-6.959266,"median":-4.434912,"eighty":-3.576816,"marketCap":963242833},{"date":"2025-07-18","current":-4.878917,"twenty":-6.905553,"median":-4.448509,"eighty":-3.590436,"marketCap":1019371645},{"date":"2025-07-25","current":-5.084011,"twenty":-6.899536,"median":-4.462257,"eighty":-3.592447,"marketCap":1062222673},{"date":"2025-08-01","current":-4.902026,"twenty":-6.889009,"median":-4.488402,"eighty":-3.59611,"marketCap":1024199930},{"date":"2025-08-08","current":-4.450911,"twenty":-6.843738,"median":-4.500505,"eighty":-3.597671,"marketCap":920510630},{"date":"2025-08-15","current":-4.924039,"twenty":-6.770823,"median":-4.509171,"eighty":-3.60188,"marketCap":1018360185},{"date":"2025-08-22","current":-4.900675,"twenty":-6.760445,"median":-4.52404,"eighty":-3.616232,"marketCap":1013528108},{"date":"2025-08-29","current":-4.883151,"twenty":-6.744059,"median":-4.5525,"eighty":-3.624946,"marketCap":1009904051},{"date":"2025-09-05","current":-4.962006,"twenty":-6.704732,"median":-4.610273,"eighty":-3.625072,"marketCap":1026212310},{"date":"2025-09-12","current":-4.731283,"twenty":-6.670975,"median":-4.650968,"eighty":-3.630649,"marketCap":978495552},{"date":"2025-09-19","current":-4.474275,"twenty":-6.670975,"median":-4.610273,"eighty":-3.651563,"marketCap":925342707},{"date":"2025-09-26","current":-4.558971,"twenty":-6.651853,"median":-4.590463,"eighty":-3.659766,"marketCap":942858985},{"date":"2025-10-03","current":-4.667031,"twenty":-6.651853,"median":-4.640746,"eighty":-3.671275,"marketCap":965207340},{"date":"2025-10-10","current":-6.182794,"twenty":-6.639187,"median":-4.66411,"eighty":-3.682866,"marketCap":1278688323},{"date":"2025-10-17","current":-6.495292,"twenty":-6.589022,"median":-4.675298,"eighty":-3.682866,"marketCap":1343317350},{"date":"2025-10-24","current":-8.382293,"twenty":-6.651853,"median":-4.679157,"eighty":-3.689208,"marketCap":1733575542},{"date":"2025-10-30","current":-8.929372,"twenty":-6.677726,"median":-4.695701,"eighty":-3.698293,"marketCap":1846719051}],"updateTime":1761899531598},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SYRE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2573611309","title":"Spyre Therapeutics Announces Promising Phase 1 Results for Novel Anti-TL1A Antibody SPY002 in Inflammatory Bowel Disease at UEGW 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573611309","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573611309?lang=en_us&edition=fundamental","pubTime":"2025-10-05 21:00","pubTimestamp":1759669215,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Announces Promising Phase 1 Results for Novel Anti-TL1A Antibody SPY002 in Inflammatory Bowel Disease at UEGW 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on October 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251005:nNDLSqbQB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B3QW5Z07.USD","BK4112","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2095319765.USD","LU0314104364.USD","NDAQ","BK4585","SYRE","LU2210149790.SGD","BK4139","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2572633851","title":"Press Release: Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2572633851","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572633851?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:05","pubTimestamp":1759521900,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Oct. 03, 2025  -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 42,500 shares of common stock of Spyre to three non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended . The stock options were approved on October 1, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635.Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease  and other immune-mediated disease products by combining best-in-cla","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBD","LENZ","NQmain","BK4539","BK4007","SYRE"],"gpt_icon":0},{"id":"2570400317","title":"Spyre Therapeutics initiated with a Buy at Deutsche Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2570400317","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570400317?lang=en_us&edition=fundamental","pubTime":"2025-09-26 16:35","pubTimestamp":1758875707,"startTime":"0","endTime":"0","summary":"Deutsche Bank initiated coverage of Spyre Therapeutics (SYRE) with a Buy rating and $43 price target The company’s goal is to create improved biolo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-initiated-with-a-buy-at-deutsche-bank-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-initiated-with-a-buy-at-deutsche-bank-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4585","BK4118","DB","SYRE","BK4566","BK4588","BK4539","BK4552","LENZ","BK4139"],"gpt_icon":0},{"id":"2570717560","title":"Spyre Therapeutics Inc : Deutsche Bank Initiates Coverage With Buy Rating; Target Price $43","url":"https://stock-news.laohu8.com/highlight/detail?id=2570717560","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570717560?lang=en_us&edition=fundamental","pubTime":"2025-09-26 14:40","pubTimestamp":1758868819,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nFWN3VD0CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2569574105","title":"JonesTrading Remains a Hold on Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2569574105","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569574105?lang=en_us&edition=fundamental","pubTime":"2025-09-24 06:25","pubTimestamp":1758666316,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Debanjana Chatterjee maintained a Hold rating on Spyre Therapeutics today. The company’s shares closed today at $16.02. Accord...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-remains-a-hold-on-spyre-therapeutics-syre-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-remains-a-hold-on-spyre-therapeutics-syre-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2567634103","title":"Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE), Xtant Medical Holdings (XTNT) and Akeso, Inc. (HK:9926)","url":"https://stock-news.laohu8.com/highlight/detail?id=2567634103","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567634103?lang=en_us&edition=fundamental","pubTime":"2025-09-16 17:03","pubTimestamp":1758013424,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Spyre Therapeutics (SYRE – Research Report), Xtant M...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-spyre-therapeutics-syre-xtant-medical-holdings-xtnt-and-akeso-inc-hk9926-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-spyre-therapeutics-syre-xtant-medical-holdings-xtnt-and-akeso-inc-hk9926-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4198","XTNT","BK4137","BK4139","HCSG","SYRE"],"gpt_icon":0},{"id":"2567119409","title":"Spyre Therapeutics Launches Phase 2 SKYWAY Trial of Pioneering Anti-TL1A Antibody SPY072 for Rheumatic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2567119409","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567119409?lang=en_us&edition=fundamental","pubTime":"2025-09-15 20:00","pubTimestamp":1757937656,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc., a clinical-stage biotechnology company, has announced the initiation of the Phase 2 SKYWAY basket trial for its investigational antibody, SPY072. This trial is designed to evaluate the efficacy of SPY072 in patients with moderate-to-severely active rheumatoid arthritis , psoriatic arthritis , and axial spondyloarthritis . SPY072, which targets the TL1A cytokine, offers a potential new therapeutic option with quarterly or twice-yearly subcutaneous dosing. The trial aims to address the unmet need for durable remission in these conditions, which currently affect millions of patients globally. Proof-of-concept data for these indications are anticipated in 2026. Additionally, Spyre Therapeutics is conducting the SKYLINE study, and together with SKYWAY, expects to deliver nine proof-of-concept readouts between 2026 and 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL4q1bCz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKPKM429.USD","BK4588","SYRE","IE00B3QW5Z07.USD","BK4112","LU2095319765.USD","IE00B64PRP62.GBP","LU2210150020.SGD","NDAQ","LU0314104364.USD","LU2210149790.SGD","BK4585","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2567192451","title":"Spyre Therapeutics Doses First Patient in Pioneering Phase 2 Skyway Basket Trial of Spy072, the First Anti-Tl1a Antibody Studied in Rheumatic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2567192451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567192451?lang=en_us&edition=fundamental","pubTime":"2025-09-15 20:00","pubTimestamp":1757937601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nTUA13PWJN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2564317718","title":"CFO Scott L. Burrows Reports Disposal of Common Shares of Spyre Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2564317718","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564317718?lang=en_us&edition=fundamental","pubTime":"2025-09-04 06:53","pubTimestamp":1756940032,"startTime":"0","endTime":"0","summary":"Scott L. Burrows, Chief Financial Officer of Spyre Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDLYJz5X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"1129665977","title":"Stock Track | Spyre Therapeutics (SYRE) Plummets 5.16% as Q2 Results Show One-Time Gain and Rising R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=1129665977","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129665977?lang=en_us&edition=fundamental","pubTime":"2025-08-06 22:39","pubTimestamp":1754491147,"startTime":"0","endTime":"0","summary":"Shares of Spyre Therapeutics Inc (SYRE) plummeted 5.16% in intraday trading on Wednesday following the release of its second-quarter 2025 financial results. The clinical-stage biotechnology company,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SYRE"],"gpt_icon":0},{"id":"2549546083","title":"IBM rolls out new chips and servers, aims for simplified AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2549546083","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549546083?lang=en_us&edition=fundamental","pubTime":"2025-07-08 19:00","pubTimestamp":1751972400,"startTime":"0","endTime":"0","summary":"IBM rolls out new chips and servers, aims for simplified AIBy Stephen Nellis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nL6N3T40QO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDD","SNVD.UK","LU1116320737.USD","NVD2.UK","LU1242518931.SGD","LU0640476718.USD","LU2403377893.USD","NVDY","SG9999000418.SGD","LU0082616367.USD","LU0689626769.HKD","LU0345770993.USD","LU1868837300.USD","LU0029864427.USD","LU1861215975.USD","IE0004445015.USD","NVD","NVDS.UK","NVDU","LU0057025933.USD","IE00BJLML261.HKD","IBM","NVIW.SI","LU0175139822.USD","LU1721428933.USD","SGXZ23171101.USD","LU1935042488.USD","SG9999015358.SGD","IE00BJJMRY28.SGD","LU1861220033.SGD","SYRE","NVDX","LU0942090050.USD","LU1261432733.SGD","LU1712237335.SGD","LU1244550221.USD","LU2237957902.USD","LU0106261372.USD","2NVD.UK","LU1852331112.SGD","LU1244550494.USD","NVD3.UK","LU1035775433.USD","LU2360106780.USD","3NVD.UK","NVDS"],"gpt_icon":1},{"id":"2544926681","title":"U.S. RESEARCH ROUNDUP-American Airlines, Jabil, Lennar","url":"https://stock-news.laohu8.com/highlight/detail?id=2544926681","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544926681?lang=en_us&edition=fundamental","pubTime":"2025-06-18 16:01","pubTimestamp":1750233710,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-American Airlines, Jabil, LennarJune 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including American A","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nL4N3SL0JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0831103253.SGD","BK4588","LU1023061713.HKD","BK4500","HON","LU0149721374.USD","LU0348735423.USD","GNW","BK4150","LU1169589451.USD","HSBA.UK","BK4539","LU0307460666.USD","LU1051770623.HKD","SYRE","LU1814569148.SGD","LU0417516738.SGD","LU1668664300.SGD","BK4585","LU0314104364.USD","SGXZ31699556.SGD","LU0572940350.SGD","BK4512","LU2091194634.USD","SG9999014880.SGD","IE00BJT1NW94.SGD","CAVA","SGXZ99366536.SGD","DAL","JBL","LU1019632923.USD","LU0264606111.USD","UAL","LU1861215975.USD","LUV","FLUT","SG9999018857.SGD","BK4559","BK4550","AAL","BK4088","LEN","LU2449936058.SGD","SGXZ51526630.SGD","IE0002141913.USD","LU1015430645.USD","SG9999014906.USD","LU1481107354.HKD","SRPT"],"gpt_icon":1},{"id":"2544096170","title":"Spyre Therapeutics Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2544096170","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544096170?lang=en_us&edition=fundamental","pubTime":"2025-06-17 19:30","pubTimestamp":1750159845,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases. Spyre Therapeutics, Inc. , a clinical-stage biotechnology company, has announced positive interim results from its Phase 1 trials for two novel extended half-life monoclonal antibodies, SPY002 and SPY072, targeting TL1A. These results were presented on June 17, 2025, during a conference call and webcast. The antibodies demonstrated good tolerability, a half-life of approximately 75 days, and effective target engagement for up to 20 weeks. In addition, Spyre has initiated the SKYLINE-UC platform trial, evaluating treatments for ulcerative colitis, and plans to start the SKYWAY-RD basket trial in Q3 2025, which will assess SPY072 in several rheumatologic conditions. Topline proof-of-concept data are expected in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUB","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL2NYgl5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2544988315","title":"Spyre Therapeutics Inc. to Announce Results for the First Quarter 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2544988315","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544988315?lang=en_us&edition=fundamental","pubTime":"2025-06-17 04:05","pubTimestamp":1750104326,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on June 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL2Km46k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2541989088","title":"Spyre Therapeutics Announces Inducement Stock Option Grants for New Employees Under 2018 Equity Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2541989088","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541989088?lang=en_us&edition=fundamental","pubTime":"2025-06-07 04:05","pubTimestamp":1749240318,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc., a clinical-stage biotechnology company, announced on June 6, 2025, that its independent Compensation Committee has approved the grant of stock options to three non-executive employees. The inducement awards, granted under the company's 2018 Equity Inducement Plan, allow for the purchase of 50,200 shares of common stock at an exercise price of $15.40 per share, consistent with the closing price on June 2, 2025. These options come with a 10-year term and vest over a four-year period, beginning with one-fourth of the shares after the first year of employment, followed by monthly vesting of one-forty-eighth of the shares. These terms are contingent upon continuous service with Spyre.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL9M7CFf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2540671803","title":"Spyre Therapeutics Inc. Convened Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540671803","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540671803?lang=en_us&edition=fundamental","pubTime":"2025-06-03 04:02","pubTimestamp":1748894560,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc. held its Annual Meeting of Stockholders on May 29, 2025. During the meeting, stockholders elected Peter Harwin, Michael Henderson, and Sandra Milligan as Class III directors. The stockholders also ratified the appointment of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2025. All proposals were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL6FDdPB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2538768664","title":"Spyre Therapeutics Inc. to Participate in Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2538768664","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538768664?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:30","pubTimestamp":1748435426,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc. , a clinical-stage biotechnology company, is set to participate in the Jefferies Global Healthcare Conference on June 4, 2025. The company, known for its advancements in antibody engineering and therapeutic combinations for the treatment of Inflammatory Bowel Disease and other immune-mediated diseases, will have its management present at a fireside session scheduled for 8:10 am ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on May 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL5Hfr2m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2534913162","title":"Spyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2534913162","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534913162?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:55","pubTimestamp":1746737755,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummarySpyre Therapeutics Inc SYRE.OQ reported a quarterly adjusted loss of 60 cents per share for the quarter ended Ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nL8N3RG3HT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":38,"code":"91000000","status":"200"}]}}